Fruit Street, a leader in delivery of the CDC's National Diabetes Prevention Program, today announced the immediate appointment of Emily Chapman as Senior Vice President of Strategy & Sales. NEW YORK, Oct. 20, 2025 /PRNewswire-PRWeb/ -- Fruit Street, a leader in delivery of the CDC's National Diabetes Prevention Program, today announced the immediate appointment of Emily Chapman as Senior Vice President of Strategy & Sales. Chapman brings more than 25 years of executive experience in sales, marketing, and b ...

BURLINGTON, Mass. & NEW YORK--(BUSINESS WIRE)---- $BFLY #POCUS--Butterfly Network, Inc. (NYSE: BFLY) ("Butterfly†), a digital health company transforming care with handheld, whole-body ultrasound and intuitive software, today announced that it will report third quarter 2025 financial results on October 31, 2025 before the market opens. Joseph DeVivo, President, Chief Executive Officer and Chairman of the Board, and Megan Carlson, Interim Chief Financial Officer, will host a conference call and webcast at ...

公司收购事件 - 三星电子收购领先的数字健康平台Xealth [1] - 此次收购旨在推进公司在互联护理领域的愿景 [1]

公司近期动态 - 公司已聘请FN Media集团于2025年10月20日当周开始为期三天的新闻/媒体营销活动，合同金额为14,085美元 [1] - FN Media将使用其专有的流量生成应用及Google/Yahoo数字广告平台，且与公司无任何利益关联 [2] 公司业务与技术核心 - 公司提供由医生构建、人工智能驱动的解决方案，旨在让高质量医疗保健服务覆盖患者诊疗全过程 [3] - 公司技术的基石是全球医学图书馆（GLM），这是一个经过临床验证的决策支持系统，由全球数百名医生参与开发 [3] - 公司拥有AI驱动的数字健康平台和市场，已赋能超过300名医生为超过70万次患者就诊提供服务 [4] - 公司的专有技术软件和系统使医生能够独立启动和管理其虚拟或混合线下诊所，从而提升效率、恢复医生自主权并扩大患者就医机会 [4] 公司使命与市场定位 - 公司技术通过减少行政负担和确保更高的一致性，为有意义的医患互动创造更多时间 [5] - 公司致力于服务加拿大缺乏家庭医生的医疗服务不足、农村和偏远社区，以及支持美国医疗补助和医疗保险的患者 [5] - 公司利用先进AI、大语言模型和联网医疗设备，重新定义现代医疗保健，使其更具可扩展性、公平性和以患者为中心 [5]

公司财务信息 - 公司计划于2025年10月30日交易结束后公布2025年第三季度财务业绩 [1] - 管理层将于太平洋时间下午1:30（东部时间下午4:30）举行相应的财报电话会议 [1] 投资者关系 - 相关方可通过公司投资者关系网站的“季度业绩”栏目观看电话会议的网络直播及回放 [2] 公司业务概览 - 公司是一家领先的数字医疗保健公司，致力于创建用于检测、预测和预防疾病的可信解决方案 [3] - 公司通过结合可穿戴生物传感器、基于云的数据分析和强大的专有算法，将数百万次心跳数据转化为具有临床价值的信息 [3] - 公司的愿景是通过对患者护理的不懈关注，为所有人提供更好的数据、更好的见解和更好的健康 [3]

公司股价表现 - 公司股价在周三大幅上涨1618% 收于每股6276美元 [1] - 公司是周三表现最佳的股票之一 [1] 业务发展驱动因素 - 公司正式推出了针对女性健康史和个人偏好定制的新更年期和围绝经期治疗方案 [1] - 投资者对公司乐观预期表示欢迎 公司预计其女性健康业务收入将在2026年超过10亿美元目标 [1] - 公司拥有超过50万订阅用户 新产品预计将支持其2026年Hers收入目标 [3] 产品与服务细节 - 针对符合条件的客户 个性化治疗方案可能包括药丸、贴片或乳霜形式的处方药 [2] - 治疗方案可能包含雌二醇 一种人体自然产生的激素 有助于缓解潮热和盗汗等更年期症状 [2] - 治疗方案还可能包含孕激素 有助于保护子宫内膜并改善睡眠质量 [2] 公司战略与愿景 - 公司首席医疗官表示 改变女性医疗保健体验始于增加获得专门护理各生命周期女性的医疗服务提供者的机会 [3] - 作为最大的数字健康平台之一 公司致力于改变女性体验医疗保健的方式并帮助她们茁壮成长 [3]

Key Points The next-generation healthcare services specialist has launched offerings in a new segment. This is laser-focused on female health. These 10 stocks could mint the next wave of millionaires › Healthcare products specialist Hims & Hers Health (NYSE: HIMS) stock passed the most crucial exam of all on Wednesday, as investors gave it the thumbs-up. The shares ended the day more than 16% higher in price, thanks to the company's reveal that it's pushing into a potentially lucrative new segment. ...

"We're transforming medical-level intelligence into tools that fit people's daily lives," said Marshall Perkins, CEO. "This creates a bridge between research-grade AI and mass-market accessibility while generating early revenue potential." About Medical Care Technologies Inc. Press Alt+1 for screen-reader mode, Alt+0 to cancelAccessibility Screen-Reader Guide, Feedback, and Issue Reporting | New window Contact Us Back to the Newsroom Medical Care Technologies Inc. (OTC PINK:MDCE) Expands App Library With Ne ...

Initial target markets for commercialization include Germany, the Benelux countries, Austria, the United Kingdom, and Scandinavia Expands distributor channel coverage to ~35% of European Union population with ~300,000 annual endovascular procedures BERKELEY, Calif, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an individual’s bio ...

Initial target markets for commercialization include Germany, the Benelux countries, Austria, the United Kingdom, and Scandinavia Expands distributor channel coverage to ~35% of European Union population with ~300,000 annual endovascular procedures BERKELEY, Calif, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an individual’s bio ...